BioSyent Inc. (CVE:RX – Free Report) – Research analysts at Bloom Burton upped their Q3 2023 earnings estimates for shares of BioSyent in a research report issued on Wednesday, August 23rd. Bloom Burton analyst D. Martin now anticipates that the company will post earnings of $0.10 per share for the quarter, up from their prior estimate of $0.09. The consensus estimate for BioSyent’s current full-year earnings is $0.43 per share. Bloom Burton also issued estimates for BioSyent’s FY2023 earnings at $0.21 EPS.
BioSyent (CVE:RX – Get Free Report) last released its quarterly earnings data on Friday, May 26th. The company reported C$0.10 earnings per share for the quarter, missing the consensus estimate of C$0.13 by C($0.03). The company had revenue of C$6.48 million during the quarter, compared to the consensus estimate of C$7.60 million. BioSyent had a net margin of 18.43% and a return on equity of 15.42%.
BioSyent Stock Performance
BioSyent Company Profile
BioSyent Inc, a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water or mixing oral iron supplement; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia.
- Five stocks we like better than BioSyent
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- 2 Stocks to Get You Ready for the Holiday Season
- How to Invest in Electric Cars
- Profit Potential: 5 Undervalued Stocks With High Dividend Yields
- Utilities Stocks Explained – How and Why to Invest in Utilities
- MarketBeat Week in Review – 8/21 – 8/25
Receive News & Ratings for BioSyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSyent and related companies with MarketBeat.com's FREE daily email newsletter.